Welcome to our dedicated page for Evoke Pharma SEC filings (Ticker: EVOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evoke Pharma, Inc. filings document the company’s completed acquisition by QOL Medical, including material definitive agreement disclosures, tender-offer and merger completion records, common-stock capital structure, and Nasdaq-listed security information before trading ceased. The filing record also includes 8-K disclosures for quarterly financial results and operating updates.
Other Evoke filings record company-specific events tied to GIMOTI, including USPTO patent activity, FDA Orange Book listing plans, and intellectual-property coverage for intranasal metoclopramide in gastroparesis patients. Governance, risk-factor, shareholder, and transaction disclosures appear through material-event reports and related exhibits.
Evoke Pharma reported Q3 2025 results with net product sales of $4,283,979, up from $2,654,186 a year ago. The company recorded a net loss of $1,156,208 for the quarter and $4,033,362 for the nine months. Cash and cash equivalents were $11,576,010 as of September 30, 2025.
Stockholders’ equity was $3,362,236, down from $7,038,010 at year-end. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses and potential termination rights under the Eversana agreement. Current liabilities include a $5,000,000 note payable and accrued interest of $2,487,638.
Subsequent events: the company entered a Merger Agreement with QOL Medical, featuring a cash tender offer of $11.00 per share, with closing expected in Q4 2025 subject to conditions. Upon change of control or expiration of the Eversana agreement, outstanding principal and interest become due and an additional $1.0 million is payable. Shares outstanding were 1,722,409 as of November 6, 2025.
Evoke Pharma (EVOK) insider transaction: Roger Klein reported open‑market sales on 11/06/2025, including 5,000 shares at a weighted average price of $10.657 and 4,000 shares at $10.65.
After these trades, 29,000 shares were beneficially owned by his Roth IRA and 125,000 shares by the Krieger Charitable Trust, for which he is sole trustee. He disclaims beneficial ownership except to the extent of his pecuniary interest.
Evoke Pharma (EVOK): Roger Klein filed a Form 3, the initial statement of beneficial ownership, with a date of event of 11/04/2025. He is identified as a Director.
The filing lists Common Stock 34,000 held indirectly by his Roth IRA and Common Stock 129,000 held indirectly by the Krieger Charitable Trust, for which he is sole trustee. The filing notes a disclaimer of beneficial ownership except to the extent of his pecuniary interest.
Evoke Pharma announced a planned cash tender offer by QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC, to acquire all outstanding shares of Evoke Pharma common stock. The transaction would proceed under an Agreement and Plan of Merger dated November 3, 2025.
The tender offer has not yet commenced. The buyer will file a Schedule TO with an offer to purchase and related documents, and Evoke Pharma will file a Schedule 14D-9. Investors are urged to read these materials carefully when available on the SEC’s website, as they will include the terms and conditions of the offer.
Evoke Pharma signed a definitive Agreement and Plan of Merger under which QOL Medical will launch a tender offer to acquire all outstanding shares for $11.00 in cash per share, subject to customary conditions. The Board unanimously approved the deal and recommends stockholders tender their shares.
The offer will be open for at least 20 business days and requires more than 50% of outstanding shares (with certain exercised options/warrants counted) to meet the minimum condition. Support agreements cover approximately 10.4% of outstanding shares. Following completion, Evoke will merge into a QOL subsidiary under DGCL 251(h), become wholly owned by QOL, and cease to be publicly traded.
The agreement includes standard terms, an outside date of May 3, 2026, and a $1.5 million termination fee under specified circumstances. An Eversana letter agreement provides for payment of $1.0 million of outstanding Cumulative Deferred Costs and loan principal and interest following a change of control or CSA expiration. Equity awards will be cashed out as described, and out‑of‑the‑money warrants receive no consideration unless Black Scholes value is elected.
Morgan Stanley and its affiliate Morgan Stanley Smith Barney LLC report beneficial ownership of 163,718 shares of Evoke Pharma Inc. common stock, representing 10.5% of the class. The filing shows no sole voting or dispositive power and shared dispositive power of 163,718 shares, indicating holdings reported on behalf of Morgan Stanley reporting units. The filing is submitted on a Schedule 13G basis and includes exhibits for a joint filing agreement and subsidiary identification.
Evoke Pharma, Inc. filed a current report to note that it issued a press release on August 14, 2025 announcing its financial results for the three- and six-month periods ended June 30, 2025. The press release is provided as Exhibit 99.1 to the report and is incorporated by reference, while the company clarifies that this earnings information is being furnished rather than filed for liability purposes under the securities laws.
Evoke Pharma reported continued commercial progress for Gimoti with accelerating product sales but persistent operating losses and a constrained cash runway. Net product sales were $3,752,142 for the quarter and $6,832,300 for the six months ended June 30, 2025. The company recorded a net loss of $1,570,976 for the quarter and $2,877,154 for the six-month period, reducing stockholders' equity to $4,374,492 and an accumulated deficit of $131,668,786. Cash and cash equivalents totaled $12,059,072 at period end.
The company has a $5.0 million note payable and accrued interest bringing the loan balance to $7.4 million as of June 30, 2025, and reports approximately $79.8 million of unreimbursed commercialization costs to its commercial partner, Eversana. Management discloses substantial doubt about the ability to continue as a going concern and expects current cash and forecasted net sales to fund operations into the third quarter of 2026 under the current plan.